Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
62.97
+3.13 (5.23%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Rhythm Pharmaceuticals Revenue
In the year 2024, Rhythm Pharmaceuticals had annual revenue of $130.13M with 68.06% growth. Rhythm Pharmaceuticals had revenue of $41.83M in the quarter ending December 31, 2024, with 72.61% growth.
Revenue (ttm)
$130.13M
Revenue Growth
+68.06%
P/S Ratio
29.52
Revenue / Employee
$459,809
Employees
283
Market Cap
3.98B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
RYTM News
- 1 day ago - Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - GlobeNewsWire
- 16 days ago - Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder - Seeking Alpha
- 17 days ago - Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - Reuters
- 17 days ago - Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewsWire
- 18 days ago - Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewsWire